Investing.com - Financial Markets Worldwide

BD to separate Biosciences and Diagnostic Solutions business

Published 05/02/2025, 22:42
© Reuters.
BDX
1.48%

Investing.com -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology firm, has announced that its board of directors has unanimously authorized a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of the company. This move aims to enhance strategic focus and growth-oriented investments for both BD and the separated business, as well as to enhance value creation for shareholders.

Tom Polen, chairman, CEO, and president of BD, stated that the company’s 2025 strategy has positioned it as a rapidly growing, profitable organization at the forefront of long-term growth trends in health care. He added that the separation is an exciting next step in unlocking significant potential value for all stakeholders. The plan is to position the New BD as a differentiated MedTech leader and enable optimized investment to accelerate the innovation pipeline and ongoing margin enhancement through BD Excellence to further fund growth.

Polen also said that the Biosciences and Diagnostic Solutions business is expected to deliver substantial value as a pure-play leader in life sciences and will be well-positioned to execute on its unique and compelling solutions and growth opportunities. The transaction is designed to position both businesses to thrive in their respective sectors and deliver value for shareholders.

The decision to separate came as a result of a comprehensive business portfolio evaluation launched by BD in early 2024. The company believes that the separation will unlock value on two fronts: The creation of a New BD that is recognized as a focused, innovative, and growth-oriented medical technology leader with four attractive segments aligned to both essential needs and higher-growth trends in health care, and the Biosciences and Diagnostic Solutions business that is expected to become a differentiated leader in Life Sciences Tools and Diagnostics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.